New long-term data from Novartis’s Zolgensma and Roche’s Erysdi will help close the gap on Biogen’s market leader Spinraza, but the three therapies look set to develop distinct or even complementary roles as the market matures.

The US biotech is facing yet another setback on its journey to proof-of-concept for its proprietary gene editing technology as two pharma firms back out of collaborations in the neurological space.

“There’s no one company, government, person or technology who is positioned to ‘solve’ the health of the world,” notes Haleon's Nick Tate. Which is why OTC companies are partnering with tech firms large and small to create the next generation of consumer healthcare products and services. In the first part of an exclusive interview on the future of digital consumer health, Tate – who heads up the firm’s incubator business, Haleon NEXT – discusses some of complications of tech innovation that make such collaboration attractive.

Investors love an opportunity to invest in a recovery play after the disclosure of bad news but, having lived in recent years under a succession of clouds, will generic drug companies begin to see biosimilars resurrect their sales growth?